AzTrials
AzTrials

KeratoconusNCT03619434

Femtolaser Assisted Keratoplasty Versus Conventional Keratoplasty

A study testing Femtosecond Laser and Trephine blade in people with Keratoconus and Fuchs Dystrophy, run by University of Southampton at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This pilot study will compare upto 15 patients undergoing femtolaser assisted keratoplasty (using CE[Conformité Européene] approved femtolaser apparatus) with upto 15 patients undergoing conventional keratoplasty with a manual trephine. Patients will be randomly assigned to either group. Read more about this study

Who is it for?
Ages 16 to 90 years
Conditions the study is for
Keratoconus, Fuchs Dystrophy, Corneal Disease
What is being tested?
Femtosecond Laser and Trephine blade
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited Kingdom
Study dates
1 Feb 2019to 26 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 90 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Eyes with corneal opacities owing to previous corneal pathology.

Who cannot join

  • Eyes with concomitant ocular pathology which may affect visual acuity.
  • Eyes who received previous corneal grafts.

Trial locations and contacts

1 site in 1 country.

Parwez N Hossain, MB ChB, PhD contact

02381204270

P.N.Hossain@soton.ac.uk

United Kingdom1 site, 1 recruiting
  • Southampton Eye Unit

    Southampton, Hampshire, SO16 6YD

    Parwez Hossain, MhCHb, PhD, 02381204270, P.N.Hossain@soton.ac.uk

    Parwez Hossain, MhCHb, PhD

    Recruiting

Other trials in United Kingdom

About this study

Official title: Pilot Study of Femtolaser Assisted Keratoplasty Versus Conventional Keratoplasty

This pilot study will compare upto 15 patients undergoing femtolaser assisted keratoplasty (using CE[Conformité Européene] approved femtolaser apparatus) with upto 15 patients undergoing conventional keratoplasty with a manual trephine. Patients will be randomly assigned to either group. All keratoplasties will be penetrating keratoplasties. The following aims of this research is detailed below:

  1. Does femtosecond laser assisted keratoplasty ( FLAK ) yield faster visual recovery and better long term BCVA (Best Corrected Visual Acuity)?
  2. Does FLAK offer a biomechanically stronger cornea and thereby more safety and less risk of wound dehiscence?
  3. Is there any difference between FLAK and conventional keratoplasty in terms of graft failure or rejection?
Read more

Follow up in best corrected visual acuity, various refraction/astigmatism measurements, intraocular pressure, graft rejection/failure rates, pachymetry and corneal hysteresis and resistance factor will be recorded at 1 day, 1 week, 1, 3 and 6 months and 1 year and 18 months postoperatively.

This study, to the investigators' knowledge will be the first randomised controlled trial in this area, the first to provide an empirical measurement to biomechanical stability of the cornea with the femtolaser, and the first done in an NHS (National Health Service) setting.

Read the detailed description

Introduction The femtosecond laser has had a profound effect on refractive surgery and, more recently, on cataract surgery and cornea transplantation. The superior precision and control offered by femtosecond laser and its potential use in cornea transplantation show promise in terms of wound stability and strength.

By doing this research project the investigators aim to answer the following questions:

  1. Does femtosecond laser assisted keratoplasty ( FLAK ) yield faster visual recovery and better long term BCVA?
  2. Does FLAK offer a biomechanically stronger cornea and thereby more safety and less risk of wound dehiscence?
  3. Is there any difference between FLAK and conventional keratoplasty in terms of graft failure or rejection?

There have been other studies that have compared femtolaser to the manual trephine in corneal transplant keratoplasty surgery. The investigators' study, to their knowledge, will be the first randomised controlled trial in this area. The majority of interventional studies comparing the two procedures are retrospective case controls. This study, will also be the first to provide an empirical measurement to the biomechanical stability of corneas that have undergone femtolaser corneal transplant. Although theorised to be better with the femtolaser, there has yet to have been a comparative study that has utilised quantitative evidence supporting this. By measuring postoperative corneal hysteresis and corneal resistance factor using an ocular response analyser, the investigators hope to be able to do that.

Recruitment, inclusion/exclusion and method Patients attending the cornea firm at the eye unit in University Hospitals Southampton who are indicated for penetrating keratoplasty as a result of corneal disease or pathology will be recruited. The participants have no connection to the university or the researcher that is known before the research starts. The aim for this study is to have a minimum of 10 patients recruited altogether and a maximum of 30.

Inclusion criteria: • Eyes with corneal opacities owing to previous corneal pathology.

Exclusion criteria: • Eyes with concomitant ocular pathology which may affect visual acuity.

  • Eyes who received previous corneal grafts. Only after the patient has given their informed consent and confirmation that they meet the criteria will they be formally included in the study.

After inclusion in the study participants will be randomised into two groups of equal numbers to either undergo femtolaser-assisted penetrating keratoplasty or to undergo conventional keratoplasty. Other than the use of instrument to make incisions for the graft on the host cornea, all other aspects of the surgery will be kept as homogenous as possible.

Patients will stay overnight or have this operation done as a day case depending on time of day the operation is done. They will then be followed up at 1 day, 1 week, 1 months, 3 months, 6 months, 12 months and 18 months in various different visual outcome measurements as well as biomechanical measures of corneal healing. The two groups will be statistically compared at each timepoint.

This study also has a further role as a pilot study to assess the feasibility of doing a study like this on a larger scale, as a randomised, controlled trial.

Consent Patients who are deemed to not have capacity will not be eligible for this study as they cannot proceed with the consent form. All staff involved in the study have appropriate training in how to judge capacity.

For those with capacity, they will read the patient information sheet first. The patient information sheet contains in layman's terms full details for potential research participants, covering issues from why the researchers are doing the study, what the researchers expect from them, the possibility of adverse effects and anonymity and confidentiality. If patients are still interested after that they will receive a consent form to be signed by them. They will be given a copy of the signed consent form to keep.

Risks, burdens and benefits Risks are explained in the patient information sheet so patients have a fully informed decision about whether to take part in the study. From the investigators point of view it is important to note these patients for this study are indicated for corneal transplant surgery - that is it is felt the benefits of a conventional surgery outweighs the normal risks of corneal transplant surgery. Femtolaser keratoplasty is not known to add any risks that is not present in conventional keratoplasty. It is CE approved for the use in creating cuts in the cornea, as the surgeons are doing for corneal transplants.

Confidentiality The nature of this study means that their details will be known to the surgeons and staff performing the surgery in data collection but these will be coded/anonymised for members of the team involved in other parts of the study, leaving the number of people who know linking details to a minimum. Any documents linking the patient's details to the code will only be the responsibility of the surgeons and their staff. The consent forms themselves will be kept inside a locked storage unit in the Southampton Eye Unit. The patients will be reassured their personal details will not be known to any of the researchers other than the surgeons and their staff that will carry out the surgery.

Being tested
Femtosecond Laser, Trephine blade
Keywords
Femtolaser, Corneal Transplant, Keratoplasty, Corneal Graft, Laser, Trephine
Medical subject headings
Keratoconus, Fuchs' Endothelial Dystrophy, Corneal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Femtosecond LaserProcedure or surgery

    The laser will be used to make incisions in the cornea for the graft.

  • Trephine bladeProcedure or surgery

    A trephine blade will be used to make incisions in the cornea for the graft

Study groups in NCT03619434
Study groupRoleWhat they receive
Conventional keratoplasty group (Control)Active comparatorThis group will undergo conventional penetrating keratoplasty with a trephine blade.
Receives: Procedure: Trephine blade
Femtolaser groupExperimentalThis group will undergo femtosecond laser-assisted penetrating keratoplasty.
Receives: Procedure: Femtosecond Laser

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Best Corrected Visual Acuity

    Measure of clarity of vision

    Measured: Followed up periodically for upto 18 months

  2. Subjective refraction

    A measure of refractive error

    Measured: Followed up periodically for upto 18 months

  3. Intraocular pressure

    Fluid pressure inside the eye

    Measured: Followed up periodically for upto 18 months

  4. Corneal hysteresis

    Measure of biomechanical stability of the cornea. Will be done by one machine (Ocular Response Analyser)

    Measured: Followed up once at 3 months

  5. Corneal topography

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Measured: Followed up periodically for upto 18 months

  6. Endothelial cell density

    A measure of healing in the new graft

    Measured: Followed up periodically for upto 18 months

  7. Corneal Resistance Factor

    Measure of biomechanical stability of the cornea. Will be done by one machine (Ocular Response Analyser)

    Measured: Followed up once at 3 months

  8. Keratometry

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Measured: Followed up periodically for upto 18 months

  9. Pachymetry

    A visual outcome measure assessing corneal thickness. Will be done using a pentacam,

    Measured: Followed up periodically for upto 18 months

  10. Corneal irregularity index

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Measured: Followed up periodically for upto 18 months

  11. Astigmatism

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Measured: Followed up periodically for upto 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2018
  2. Study start1 Feb 2019
  3. Primary completion26 Dec 2021 (estimated)
  4. Study completion26 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a prospective cohort study where a maximum of 30 patients attending the cornea firm at the eye unit in University Hospitals Southampton who are indicated for penetrating keratoplasty as a result of corneal disease or pathology will be recruited. All patients will receive a complete ophthalmological examination preoperatively. Subjects will then be divided randomly into 2 groups of 15, should we get 30 patients;
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03619434
Sponsor's protocol ID
32158
Status last verified
Dec 2020
First submitted
23 Jul 2018
Last updated
22 Dec 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Femtosecond Laser and Trephine blade in people with Keratoconus and Fuchs Dystrophy, run by University of Southampton at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Parwez N Hossain, MB ChB, PhD (02381204270, P.N.Hossain@soton.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Best Corrected Visual Acuity (time frame: Followed up periodically for upto 18 months). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT03619434 | AzTrials